

5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 4

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following biomarkers are useful in the selection of therapy after front-line CDK4/6 inhibitor failure for patients with HR-positive, HER2-negative metastatic breast cancer?
 - ESR1 mutations
 - PI3K/AKT/mTOR mutations
 - BRCA mutations
 - All of the above
- Which of the following observations best characterizes the relative expression levels of ER at week 2 of imlunestrant therapy in the EMBER-2 study?
 - A substantial increase
 - No substantial difference
 - A substantial decrease
- Which of the following observations best characterizes the relative expression levels of PR and Ki-67 at week 2 of imlunestrant therapy in the EMBER-2 study?
 - A substantial decrease in PR expression only
 - A substantial decrease in Ki-67 expression only
 - A substantial decrease in both PR and Ki-67 expression
 - No substantial decrease
- What was the most commonly occurring any-grade adverse event with the recommended Phase II dose of 400 mg of imlunestrant in the EMBER-2 study?
 - Arthralgia
 - Fatigue
 - Headache
 - Breast pain
- Across all cohorts of the EMBER-2 study, approximately what proportion of patients experienced a Grade ≥ 3 adverse event with imlunestrant?
 - 4%
 - 12%
 - 25%
 - 41%